Sep 19, 2006|
Markets: Where to from here?
After the sharp correction witnessed on the Indian bourses towards the end of May and in June, the indices have once again crossed the 12,000 milestone. That said, the journey has been a rough one with concerns over rising crude prices and interest rates, both globally and in India and India-specific events such as terrorism (read the bomb blasts in Mumbai), monsoon mayhem across parts of the country keeping investors and the common man alike on their toes. In this article, we take a look at the performance of some of the sectoral indices in the last three months and the likely prospects going forward.
Performance in the last three months
June 14, 2006
Sep 15, 2006
Software: The BSE IT index, since its lows hit in mid-June, has gained 42%. Undoubtedly, at that time, significant and mouth-watering buying opportunities had emerged in these stocks. It must be noted that Infosys, Satyam, TCS, Wipro and HCL Tech collectively account for over 90% of the weightage of the BSE IT index, and the strong stock performance of these companies has meant that the overall index has also moved up significantly. As regards valuations, we believe that most of these stocks have run up quite a bit, and are fairly valued in the near-term, taking into account growth prospects adjusted for risk. However, from a long-term perspective, we believe that these top-tier software companies, with their superior scalable business models and stronger operating metrics relative to their mid-sized peers, will benefit more from the offshoring story, and we remain positive overall on the sector.
Banking: Banking stocks have been amongst the forerunners in the rally witnessed on the bourses over the past three months. The reasons that can be cited for the same are reiteration of confidence in fundamentals and improved valuations. The severe liquidity crunch reported by various monetary agencies (including the RBI) had led to investors speculating a slow down in deposit growth and resultantly pressure on NIMs (partly due to rise in interest rates). However, the 1QFY07 results reported no change in the fundamentals of the larger banking entities and reinforced investor confidence in them. Also, although concerns regarding NIMs and asset quality continue to linger, the valuations adhered to the banking entities (especially the PSU ones) have considerably improved, leading to the run-up in prices.
Auto: The auto index has registered gains of 29%. This was seemingly on the back of the continued robust sales numbers being posted by auto companies across segments. It was being feared that with inflationary factors in the form raw material cost escalation, crude oil prices, interest rate hikes looming large before the sector, the performance might witness a downward spiral. The fears however proved to be unwarranted as auto sales have remained firm and have thus enabled the companies to mitigate the effects of higher input costs. Moreover, courtesy the cyclical upswing in segments such as CVs and passenger vehicles, sector companies have pared debt on the balance sheet to a significant extent and hence have not been affected much by the rise in interest rates. Going forward, however, we expect pressure on the cash flows, as most of the companies have substantial capex plans lined up. Further, if the growth in the industry does not pan out along the expected lines, break even for the new capacities might just get prolonged.
Healthcare: The healthcare index notched gains of 27% during the said period. While the first few months of 2006 saw most of the major pharma companies being fairly valued, the correction in May and June brought down the valuations of these companies to reasonable levels. Since then, a slew of factors have contributed to the rise in the healthcare index. Positive developments in the global generics markets in terms of success in patent challenges have contributed favourably to the fortunes of Ranbaxy, Dr.Reddy's, Cipla and Sun Pharma. These companies posted strong results in the June quarter as well. While the performance of the MNC pharma companies left a lot to be desired in the June quarter, the raising of the ceiling for the drugs to be brought under price control by the DPCO was an encouraging sign (MNC pharma companies have a higher percentage of drugs under price control as compared to their domestic counterparts). Going forward, while we are positive about the growth prospects of both domestic and MNC companies alike, we, nevertheless, advise investors to adopt a stock-specific approach while investing in the sector.
To sum up...
We believe that at the current levels, investors need to be selective with respect to their investments and need to invest in those stocks having reasonable valuations and strong fundamentals from a long-term perspective. While the 'India' story remains intact and the growth prospects of companies have been factored in, investors need to constantly ask themselves, especially at these levels, whether the investment in a particular stock is worth the price paid.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 17, 2017
PersonalFN simplifies the mutual fund account statement for you.
Aug 17, 2017
A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.
Aug 17, 2017
Mr Trump is in the White House and the gods are in their heavens; what's not to like?
Aug 16, 2017
All across the country, the old gods become devils. New, gluten-free gods take their places...
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407